Relationship Between Serum Markers and Motor Recovery and Ambulation in Post-stroke Patients

Relationship Between Serum Markers and Motor Recovery and Ambulation in Post-stroke Patients: a Retrospective Analysis

This study aim to retrospectively investigate the effects of the magnesium, vitamin D, and uric acid serum markers on motor recovery and ambulation in post-stroke patients.

Study Overview

• Status: Completed
• Conditions: Stroke; Biomarkers; Serum Uric Acid; Serum Magnesium; Serum Vitamin D
• Intervention / Treatment: Other: Serum magnesium, uric acid, and vitamin D levels and motor recovery and ambulation stages

Detailed Description

Stroke is the sudden loss of neurological function associated with a reduction or cessation of blood flow in the brain, resulting from the blockage or rupture of cerebral vessels. Stroke is the second leading cause of death and the third leading cause of disability worldwide. Regaining motor recovery and ambulation skills in patients is one of the main goals of rehabilitation. It is critical for patients to improve their quality of life and regain their independence. Serum biochemical markers can be used to predict post-stroke recovery. Serum magnesium, vitamin D, and uric acid are biochemical markers that may play a role in the recovery process of stroke patients.

This study aim to retrospectively investigate the effects of the magnesium, vitamin D, and uric acid serum markers on motor recovery and ambulation in post-stroke patients.

• Study Type: Observational
• Enrollment (Actual): 257

Contacts and Locations

Study Locations

• Turkey
  • Bolu, Turkey, 14100
    • Abant Izzet Baysal University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients who have had a stroke for the first time and are hospitalized in the rehabilitation ward for rehabilitation purposes.

Description

Inclusion Criteria:

• Patients who had a single stroke between 2019 and 2024
• Patients who were admitted to the rehabilitation ward and had their serum vitamin D, magnesium, and uric acid levels measured
• Patients whose functional ambulation scale scores and Brunnstrom motor recovery stages were recorded

Exclusion Criteria:

• Patients with other neurological diseases
• Patients with multiple strokes
• Patients with gout, renal failure, or hyperparathyroidism

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brunnstrom Motor Recovery Stage	Brunnstrom stages is a scale used to assess motor recovery after a stroke, which is expressed using values between 1 and 6. The higher the value on this scale, the higher would be the recovery. Brunnstrom Motor Recovery Stages measured before the patients' rehabilitation will be obtained from past medical records.	Before treatment
Functional Ambulation Classification	Functional Ambulation Classification is a 6-point functional walking test that evaluates ambulation ability and determines the amount of human support required by patients while walking, regardless of whether they use a personal assistive device. A score of 0 indicates that the patient has a dysfunctional ambulation A score of 5 denotes independent ambulation on any surface. Functional Ambulation Classification Stages measured before the patients' rehabilitation will be obtained from past medical records.	Before treatment
Serum magnesium levels	Serum magnesium levels measured before the patients' rehabilitation will be obtained from past medical records.	Before treatment
Serum uric acid levels	Serum uric acid levels measured before the patients' rehabilitation will be obtained from past medical records.	Before treatment
Serum vitamin D levels	Serum vitamin D levels measured before the patients' rehabilitation will be obtained from past medical records.	Before treatment

Collaborators and Investigators

• Sponsor: Abant Izzet Baysal University

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2025
• Primary Completion (Actual): July 15, 2025
• Study Completion (Actual): July 15, 2025

Study Registration Dates

• First Submitted: July 18, 2025
• First Submitted That Met QC Criteria: July 18, 2025
• First Posted (Actual): July 25, 2025

Study Record Updates

• Last Update Posted (Actual): July 29, 2025
• Last Update Submitted That Met QC Criteria: July 25, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Bone Density Conservation Agents; Micronutrients; Antioxidants; Protective Agents; Vitamins; Vitamin D; Uric Acid
• Other Study ID Numbers: AIBU-FTR-SK-11

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No